Drug Profile
Ilginatinib - Nippon Shinyaku
Alternative Names: NS 018Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Nippon Shinyaku
- Developer Nippon Shinyaku; NS Pharma
- Class Antineoplastics; Pyrazines; Pyrazoles; Pyridines; Small molecules
- Mechanism of Action Janus kinase-2 inhibitors; Src-Family kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Myelofibrosis
- Discontinued Haematological disorders
Most Recent Events
- 08 Aug 2023 Ilginatinib receives Orphan Drug status for Myelofibrosis in European Union
- 20 Dec 2022 Ilginatinib - Nippon Shinyaku receives Orphan Drug status for Myelofibrosis in USA
- 14 Jul 2022 Phase-II clinical trials in Myelofibrosis (In the elderly, In adults) in Thailand, South Korea (PO) (NCT04854096)